The incidence of adrenal tumors has increased 10-fold over the past 2 decades, in parallel to the growing number of computed tomography (CT) abdominal scans (1). The observed increase in the incidence of adrenal tumors was mainly due to more frequent discovery of smaller adrenal incidentalomas in older patients (1). However, because an abdominal CT scan is usually ordered to evaluate a medical concern, imaging bias is very likely in any prevalence study that relies on the availability of imaging (1–5). Another concern is underreporting of adrenal lesions noted on CT scans. For example, Hammarstedt and colleagues (3) reported that ...


  • 1. Ebbehoj A, Li D, Kaur RJ, et al. Epidemiology of adrenal tumours in Olmsted County, Minnesota, USA: a population-based cohort study. Lancet Diabetes Endocrinol. 2020;8:894-902. [PMID: 33065059] doi:10.1016/S2213-8587(20)30314-4 CrossrefMedlineGoogle Scholar
  • 2. Cyranska-Chyrek E, Szczepanek-Parulska E, Olejarz M, et al. Malignancy risk and hormonal activity of adrenal incidentalomas in a large cohort of patients from a single tertiary reference center. Int J Environ Res Public Health. 2019;16. [PMID: 31137898] doi:10.3390/ijerph16101872 CrossrefMedlineGoogle Scholar
  • 3. Hammarstedt L, Muth A, Wängberg B, et al; Adrenal Study Group of Western Sweden. Adrenal lesion frequency: a prospective, cross-sectional CT study in a defined region, including systematic re-evaluation. Acta Radiol. 2010;51:1149-56. [PMID: 20969508] doi:10.3109/02841851.2010.516016 CrossrefMedlineGoogle Scholar
  • 4. Ichijo T, Ueshiba H, Nawata H, et al. A nationwide survey of adrenal incidentalomas in Japan: the first report of clinical and epidemiological features. Endocr J. 2020;67:141-152. [PMID: 31694993] doi:10.1507/endocrj.EJ18-0486 CrossrefMedlineGoogle Scholar
  • 5. Reimondo G, Castellano E, Grosso M, et al. Adrenal incidentalomas are tied to increased risk of diabetes: findings from a prospective study. J Clin Endocrinol Metab. 2020;105. [PMID: 31900474] doi:10.1210/clinem/dgz284 CrossrefMedlineGoogle Scholar
  • 6. Jing Y, Hu J, Luo R, et al. Prevalence and characteristics of adrenal tumors in an unselected screening population. A cross-sectional study. Ann Intern Med. 2022;175:1383-91. doi:10.7326/M22-1619 LinkGoogle Scholar
  • 7. Bancos I, Taylor AE, Chortis V, et al; ENSAT EURINE-ACT Investigators. Urine steroid metabolomics for the differential diagnosis of adrenal incidentalomas in the EURINE-ACT study: a prospective test validation study. Lancet Diabetes Endocrinol. 2020;8:773-781. [PMID: 32711725] doi:10.1016/S2213-8587(20)30218-7 CrossrefMedlineGoogle Scholar
  • 8. Prete A, Subramanian A, Bancos I, et al; ENSAT EURINE-ACT Investigators. Cardiometabolic disease burden and steroid excretion in benign adrenal tumors. A cross-sectional multicenter study. Ann Intern Med. 2022;175:325-334. [PMID: 34978855] doi:10.7326/M21-1737 LinkGoogle Scholar
  • 9. Stavropoulos K, Imprialos KP, Katsiki N, et al. Primary aldosteronism in patients with adrenal incidentaloma: is screening appropriate for everyone. J Clin Hypertens (Greenwich). 2018;20:942-948. [PMID: 29722113] doi:10.1111/jch.13291 CrossrefMedlineGoogle Scholar
  • 10. Fassnacht M, Arlt W, Bancos I, et al. Management of adrenal incidentalomas: European Society of Endocrinology clinical practice guideline in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2016;175:G1-G34. [PMID: 27390021] doi:10.1530/EJE-16-0467 CrossrefMedlineGoogle Scholar